Indian Pharma Market Map
Every major listed pharma, API, CDMO and biosimilar company — mapped by segment, growth, returns, R&D intensity and valuation. Rubicon is highlighted throughout.
Every major listed Indian pharma, API and CDMO company on one screen — as scatter-plots (to spot patterns) and a sortable table (for the detail). Rubicon is highlighted throughout.
Click a segment chip to filter. In the charts each bubble is a company (bigger = larger market cap) — hover for its name. In the table, click any column header to sort, and click a company name to open its full profile.
- Market cap
- — The company's total stock-market value (share price × number of shares).
- P/E
- — Price-to-Earnings — how many years of profit you pay for the stock. Higher = pricier / higher-growth.
- EV/EBITDA
- — Enterprise Value ÷ operating profit — a debt-aware valuation multiple.
- ROCE
- — Return on Capital Employed — profit generated per rupee of capital. Higher = more efficient.
- EBITDA margin
- — Operating profit as a % of sales — core profitability before interest, tax & depreciation.
- Revenue CAGR
- — Compound annual growth rate of sales over the period.
Growth vs Valuation
Revenue CAGR (5Y) × P/E · bubble = market cap
Quality vs Valuation
ROCE × P/E · bubble = market cap
US Exposure vs Margin
US revenue % × PAT margin · bubble = market cap
Returns vs Growth
5Y price CAGR × revenue CAGR · bubble = market cap
Company Universe
26 companies · click any column to sort · click a name for the full profile
| Ticker | Segment | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | Diversified | ₹4.3L Cr | ₹52.6K Cr | 22% | 29% | 20.5% | 6.2% | 31% | 35x | 27.0x | +22% |
| Divi's Laboratories | DIVISLAB | API | ₹1.8L Cr | ₹9.4K Cr | 10% | 32% | 22% | 2.5% | 0% | 68x | 42.0x | +10% |
| Torrent Pharmaceuticals | TORNTPHARM | Domestic Formulations | ₹1.5L Cr | ₹11.5K Cr | 25% | 32% | 27% | 5% | 10% | 68x | 42.0x | +25% |
| Cipla | CIPLA | Diversified | ₹1.1L Cr | ₹27.5K Cr | 7% | 26% | 23% | 6% | 28% | 29x | 15.0x | +7% |
| Zydus Lifesciences | ZYDUSLIFE | Diversified | ₹1.1L Cr | ₹23.2K Cr | 12% | 30% | 24% | 8.2% | 47% | 20x | 13.0x | +12% |
| Dr. Reddy's Laboratories | DRREDDY | Diversified | ₹1.1L Cr | ₹32.6K Cr | 4% | 26% | 13.6% | 8.4% | 45% | 25x | 13.0x | +4% |
| Lupin | LUPIN | Diversified | ₹1.0L Cr | ₹22.7K Cr | 25% | 23% | 30.3% | 8.2% | 36% | 18x | 12.0x | +25% |
| Mankind Pharma | MANKIND | Domestic Formulations | ₹98.1K Cr | ₹12.2K Cr | 0% | 25% | 13.5% | 2.2% | 0% | 49x | 30.0x | — |
| Aurobindo Pharma | AUROPHARMA | US Generics | ₹82.7K Cr | ₹31.7K Cr | 8% | 20% | 13% | 5% | 47% | 23x | 11.0x | +8% |
| Laurus Labs | LAURUSLABS | API | ₹74.2K Cr | ₹5.6K Cr | 18% | 20% | 17.8% | 4.6% | 0% | 83x | 30.0x | +18% |
| Biocon | BIOCON | Biosimilars | ₹66.6K Cr | ₹16.9K Cr | 1% | 27% | 3.75% | 7% | 0% | 171x | 16.0x | +1% |
| Alkem Laboratories | ALKEM | Domestic Formulations | ₹64.0K Cr | ₹13.0K Cr | 11% | 19% | 21.2% | 4.3% | 25% | 26x | 18.0x | +11% |
| Abbott India | ABBOTINDIA | Domestic Formulations | ₹55.3K Cr | ₹6.4K Cr | 10% | 26% | 46% | 0.5% | 0% | 36x | 28.0x | +10% |
| Ajanta Pharma | AJANTPHARM | Domestic Formulations | ₹38.4K Cr | ₹4.6K Cr | 19% | 27% | 32.3% | 4.8% | 23% | 36x | 26.0x | +19% |
| GSK Pharmaceuticals (India) | GLAXO | Domestic Formulations | ₹36.8K Cr | ₹3.7K Cr | 8% | 31% | 63% | 1% | 0% | 38x | 35.0x | +8% |
| J.B. Chemicals & Pharmaceuticals | JBCHEPHARM | Domestic Formulations | ₹35.1K Cr | ₹3.9K Cr | 23% | 26% | 26% | 3% | 0% | 49x | 28.0x | +23% |
| Piramal Pharma | PPLPHARMA | CDMO/CRDMO | ₹21.9K Cr | ₹9.2K Cr | 0% | 16% | 7% | 4% | 0% | 110x | 18.0x | — |
| Neuland Laboratories | NEULANDLAB | CDMO/CRDMO | ₹21.7K Cr | ₹1.5K Cr | 53% | 22% | 19% | 5% | 0% | 60x | 35.0x | +53% |
| Rubicon ResearchFOCUS | RUBI | Complex Generics | ₹21.1K Cr | ₹1.3K Cr | 81% | 20.7% | 39.9% | 10.4% | 72% | 104x | 55.0x | — |
| Pfizer (India) | PFIZER | Domestic Formulations | ₹20.7K Cr | ₹2.3K Cr | -4% | 33% | 24.2% | 1% | 0% | 27x | 28.0x | -4% |
| Eris Lifesciences | ERIS | Domestic Formulations | ₹19.5K Cr | ₹2.9K Cr | 14% | 35% | 14% | 3% | 0% | 31x | 19.0x | +14% |
| Granules India | GRANULES | API | ₹18.6K Cr | ₹4.5K Cr | 19% | 21% | 15% | 6% | 79% | 31x | 14.0x | +19% |
| Syngene International | SYNGENE | CDMO/CRDMO | ₹18.1K Cr | ₹3.6K Cr | -5% | 29% | 10.1% | 4% | 0% | 48x | 17.0x | -5% |
| Caplin Point Laboratories | CAPLIPOINT | US Generics | ₹17.8K Cr | ₹1.9K Cr | 29% | 34% | 26% | 5% | 21% | 28x | 22.0x | +29% |
| Suven Pharmaceuticals (now Cohance Lifesciences) | SUVENPHAR | CDMO/CRDMO | ₹16.5K Cr | ₹2.3K Cr | -2% | 19% | 8.4% | 4% | 0% | 83x | 35.0x | -2% |
| Alembic Pharmaceuticals | APLLTD | US Generics | ₹14.7K Cr | ₹7.3K Cr | -5% | 15.2% | 13% | 7% | 28% | 20x | 16.0x | -5% |